| Drug Name |
Bendamustine hydrochloride |
| Drug ID |
BADD_D00231 |
| Description |
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown. |
| Indications and Usage |
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. |
| Marketing Status |
Prescription |
| ATC Code |
L01AA09 |
| DrugBank ID |
DB06769
|
| KEGG ID |
D07085
|
| MeSH ID |
D000069461
|
| PubChem ID |
77082
|
| TTD Drug ID |
D01CYA
|
| NDC Product Code |
42367-521; 63459-391; 63459-390; 70225-1101; 62756-009; 48943-0019; 55111-938; 63759-0005; 61662-0006; 17337-0306; 63459-348; 54893-0003 |
| Synonyms |
Bendamustine Hydrochloride | Hydrochloride, Bendamustine | Bendamustine | Bendamustin | Cytostasan | IMET 3393 | Ribomustin | Treanda | Zimet 3393 |
